APO Research
Talk to an analyst

APO RESEARCH · REPORT

Mycosis Fungoides Therapeutics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Mycosis Fungoides Therapeutics Market Outlook and Growth Opportunities 2026

22 December 2025193 pages

Choose your research edition.

Industry ResearchMycosis Fungoides Therapeutics Industry Research Report 2026119 pages · $2,950 USDIndustry Growth & TrendsGlobal Mycosis Fungoides Therapeutics Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Mycosis Fungoides Therapeutics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032199 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Mycosis Fungoides Therapeutics Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Mycosis Fungoides Therapeutics Market Analysis and Forecast 2026-2032199 pages · $4,950 USD

Market perspective

The global Mycosis Fungoides Therapeutics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Mycosis Fungoides Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Mycosis Fungoides Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Mycosis Fungoides Therapeutics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Mycosis Fungoides Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Mycosis Fungoides Therapeutics market include Kyowa Kirin Co. Ltd., Takeda Pharmaceutical Co. Ltd., Eisai Co. Ltd., Merck & Co. Inc., Soligenix Inc., Seattle Genetics Inc., Horizon Therapeutics Plc, Helsinn Healthcare SA and Celgene Corp., among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Mycosis Fungoides Therapeutics market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Mycosis Fungoides Therapeutics and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Mycosis Fungoides Therapeutics revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Mycosis Fungoides Therapeutics market.

Mycosis Fungoides Therapeutics Segment by Company

Kyowa Kirin Co. Ltd.

Takeda Pharmaceutical Co. Ltd.

Eisai Co. Ltd.

Merck & Co. Inc.

Soligenix Inc.

Seattle Genetics Inc.

Horizon Therapeutics Plc

Helsinn Healthcare SA

Celgene Corp.

Azurity Pharmaceuticals Inc.

Mycosis Fungoides Therapeutics Segment by Type

Small Molecules

Biologics

Mycosis Fungoides Therapeutics Segment by Application

Hospital

Clinic

Other

Mycosis Fungoides Therapeutics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Mycosis Fungoides Therapeutics status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Mycosis Fungoides Therapeutics key companies, revenue, market share, and recent developments.

3. To split the Mycosis Fungoides Therapeutics breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Mycosis Fungoides Therapeutics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Mycosis Fungoides Therapeutics significant trends, drivers, influence factors in global and regions.

6. To analyze Mycosis Fungoides Therapeutics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Mycosis Fungoides Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Mycosis Fungoides Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Mycosis Fungoides Therapeutics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Mycosis Fungoides Therapeutics industry.

Chapter 3: Detailed analysis of Mycosis Fungoides Therapeutics company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Mycosis Fungoides Therapeutics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Mycosis Fungoides Therapeutics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Mycosis Fungoides Therapeutics Industry Trends Table 2. Mycosis Fungoides Therapeutics Industry Drivers Table 3. Mycosis Fungoides Therapeutics Industry Opportunities and Challenges Table 4. Mycosis Fungoides Therapeutics Industry Restraints Table 5. Global Mycosis Fungoides Therapeutics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Mycosis Fungoides Therapeutics Revenue Share by Company (2021-2026) Table 7. Global Mycosis Fungoides Therapeutics Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Mycosis Fungoides Therapeutics Key Company Manufacturing Base & Headquarters Table 9. Global Mycosis Fungoides Therapeutics Company, Product Type & Application Table 10. Global Mycosis Fungoides Therapeutics Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Mycosis Fungoides Therapeutics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Small Molecules Table 15. Significant Companies of Biologics Table 16. Global Mycosis Fungoides Therapeutics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Mycosis Fungoides Therapeutics Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Mycosis Fungoides Therapeutics Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Mycosis Fungoides Therapeutics Sales Value Share by Type (2021-2026) Table 20. Global Mycosis Fungoides Therapeutics Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Clinic Table 23. Significant Companies of Other Table 24. Global Mycosis Fungoides Therapeutics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Mycosis Fungoides Therapeutics Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Mycosis Fungoides Therapeutics Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Mycosis Fungoides Therapeutics Sales Value Share by Application (2021-2026) Table 28. Global Mycosis Fungoides Therapeutics Sales Value Share by Application (2027-2032) Table 29. Global Mycosis Fungoides Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Mycosis Fungoides Therapeutics Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Mycosis Fungoides Therapeutics Sales Value Share by Region (2021-2026) Table 32. Global Mycosis Fungoides Therapeutics Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Mycosis Fungoides Therapeutics Sales Value Share by Region (2027-2032) Table 34. Global Mycosis Fungoides Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Mycosis Fungoides Therapeutics Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Mycosis Fungoides Therapeutics Sales Value Market Share by Country (2021-2026) Table 37. Global Mycosis Fungoides Therapeutics Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Mycosis Fungoides Therapeutics Sales Value Market Share by Country (2027-2032) Table 39. Kyowa Kirin Co. Ltd. Company Information Table 40. Kyowa Kirin Co. Ltd. Business Overview Table 41. Kyowa Kirin Co. Ltd. Mycosis Fungoides Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. Kyowa Kirin Co. Ltd. Mycosis Fungoides Therapeutics Product Portfolio Table 43. Kyowa Kirin Co. Ltd. Recent Development Table 44. Takeda Pharmaceutical Co. Ltd. Company Information Table 45. Takeda Pharmaceutical Co. Ltd. Business Overview Table 46. Takeda Pharmaceutical Co. Ltd. Mycosis Fungoides Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Takeda Pharmaceutical Co. Ltd. Mycosis Fungoides Therapeutics Product Portfolio Table 48. Takeda Pharmaceutical Co. Ltd. Recent Development Table 49. Eisai Co. Ltd. Company Information Table 50. Eisai Co. Ltd. Business Overview Table 51. Eisai Co. Ltd. Mycosis Fungoides Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Eisai Co. Ltd. Mycosis Fungoides Therapeutics Product Portfolio Table 53. Eisai Co. Ltd. Recent Development Table 54. Merck & Co. Inc. Company Information Table 55. Merck & Co. Inc. Business Overview Table 56. Merck & Co. Inc. Mycosis Fungoides Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. Merck & Co. Inc. Mycosis Fungoides Therapeutics Product Portfolio Table 58. Merck & Co. Inc. Recent Development Table 59. Soligenix Inc. Company Information Table 60. Soligenix Inc. Business Overview Table 61. Soligenix Inc. Mycosis Fungoides Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Soligenix Inc. Mycosis Fungoides Therapeutics Product Portfolio Table 63. Soligenix Inc. Recent Development Table 64. Seattle Genetics Inc. Company Information Table 65. Seattle Genetics Inc. Business Overview Table 66. Seattle Genetics Inc. Mycosis Fungoides Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Seattle Genetics Inc. Mycosis Fungoides Therapeutics Product Portfolio Table 68. Seattle Genetics Inc. Recent Development Table 69. Horizon Therapeutics Plc Company Information Table 70. Horizon Therapeutics Plc Business Overview Table 71. Horizon Therapeutics Plc Mycosis Fungoides Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Horizon Therapeutics Plc Mycosis Fungoides Therapeutics Product Portfolio Table 73. Horizon Therapeutics Plc Recent Development Table 74. Helsinn Healthcare SA Company Information Table 75. Helsinn Healthcare SA Business Overview Table 76. Helsinn Healthcare SA Mycosis Fungoides Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Helsinn Healthcare SA Mycosis Fungoides Therapeutics Product Portfolio Table 78. Helsinn Healthcare SA Recent Development Table 79. Celgene Corp. Company Information Table 80. Celgene Corp. Business Overview Table 81. Celgene Corp. Mycosis Fungoides Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Celgene Corp. Mycosis Fungoides Therapeutics Product Portfolio Table 83. Celgene Corp. Recent Development Table 84. Azurity Pharmaceuticals Inc. Company Information Table 85. Azurity Pharmaceuticals Inc. Business Overview Table 86. Azurity Pharmaceuticals Inc. Mycosis Fungoides Therapeutics Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. Azurity Pharmaceuticals Inc. Mycosis Fungoides Therapeutics Product Portfolio Table 88. Azurity Pharmaceuticals Inc. Recent Development Table 89. Research Programs/Design for This Report Table 90. Authors List of This Report Table 91. Secondary Sources Table 92. Primary Sources List of Figures Figure 1. Mycosis Fungoides Therapeutics Product Image Figure 2. Global Mycosis Fungoides Therapeutics Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Mycosis Fungoides Therapeutics Market Size (2021-2032) & (US$ Million) Figure 4. Global Mycosis Fungoides Therapeutics Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Small Molecules Image Figure 8. Biologics Image Figure 9. Global Mycosis Fungoides Therapeutics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Mycosis Fungoides Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Mycosis Fungoides Therapeutics Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Clinic Image Figure 14. Other Image Figure 15. Global Mycosis Fungoides Therapeutics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Mycosis Fungoides Therapeutics Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Mycosis Fungoides Therapeutics Sales Value Share by Application (2021-2032) Figure 18. Global Mycosis Fungoides Therapeutics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Mycosis Fungoides Therapeutics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Mycosis Fungoides Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 21. North America Mycosis Fungoides Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Mycosis Fungoides Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Mycosis Fungoides Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Mycosis Fungoides Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Mycosis Fungoides Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Mycosis Fungoides Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 27. South America Mycosis Fungoides Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Mycosis Fungoides Therapeutics Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Mycosis Fungoides Therapeutics Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Small Molecules
  • Biologics
Applications
  • Hospital
  • Clinic
  • Other
Companies covered
  • Kyowa Kirin Co. Ltd.
  • Takeda Pharmaceutical Co. Ltd.
  • Eisai Co. Ltd.
  • Merck & Co. Inc.
  • Soligenix Inc.
  • Seattle Genetics Inc.
  • Horizon Therapeutics Plc
  • Helsinn Healthcare SA
  • Celgene Corp.
  • Azurity Pharmaceuticals Inc.

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Mycosis Fungoides Therapeutics Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Mycosis Fungoides Therapeutics Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Mycosis Fungoides Therapeutics Market Dynamics
  1. 2.1 Mycosis Fungoides Therapeutics Industry Trends
  2. 2.2 Mycosis Fungoides Therapeutics Industry Drivers
  3. 2.3 Mycosis Fungoides Therapeutics Industry Opportunities and Challenges
  4. 2.4 Mycosis Fungoides Therapeutics Industry Restraints
3 Mycosis Fungoides Therapeutics Market by Company
  1. 3.1 Global Mycosis Fungoides Therapeutics Company Revenue Ranking in 2025
  2. 3.2 Global Mycosis Fungoides Therapeutics Revenue by Company (2021-2026)
  3. 3.3 Global Mycosis Fungoides Therapeutics Company Ranking (2024-2026)
  4. 3.4 Global Mycosis Fungoides Therapeutics Company Manufacturing Base and Headquarters
  5. 3.5 Global Mycosis Fungoides Therapeutics Company Product Type and Application
  6. 3.6 Global Mycosis Fungoides Therapeutics Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Mycosis Fungoides Therapeutics Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Mycosis Fungoides Therapeutics Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Mycosis Fungoides Therapeutics Market by Type
  1. 4.1 Mycosis Fungoides Therapeutics Type Introduction
  2. 4.1.1 Small Molecules
  3. 4.1.2 Biologics
  4. 4.2 Global Mycosis Fungoides Therapeutics Sales Value by Type
  5. 4.2.1 Global Mycosis Fungoides Therapeutics Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Mycosis Fungoides Therapeutics Sales Value by Type (2021-2032)
  7. 4.2.3 Global Mycosis Fungoides Therapeutics Sales Value Share by Type (2021-2032)
5 Mycosis Fungoides Therapeutics Market by Application
  1. 5.1 Mycosis Fungoides Therapeutics Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Other
  5. 5.2 Global Mycosis Fungoides Therapeutics Sales Value by Application
  6. 5.2.1 Global Mycosis Fungoides Therapeutics Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Mycosis Fungoides Therapeutics Sales Value by Application (2021-2032)
  8. 5.2.3 Global Mycosis Fungoides Therapeutics Sales Value Share by Application (2021-2032)
6 Mycosis Fungoides Therapeutics Regional Value Analysis
  1. 6.1 Global Mycosis Fungoides Therapeutics Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Mycosis Fungoides Therapeutics Sales Value by Region (2021-2032)
  3. 6.2.1 Global Mycosis Fungoides Therapeutics Sales Value by Region: 2021-2026
  4. 6.2.2 Global Mycosis Fungoides Therapeutics Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Mycosis Fungoides Therapeutics Sales Value (2021-2032)
  7. 6.3.2 North America Mycosis Fungoides Therapeutics Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Mycosis Fungoides Therapeutics Sales Value (2021-2032)
  10. 6.4.2 Europe Mycosis Fungoides Therapeutics Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Mycosis Fungoides Therapeutics Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Mycosis Fungoides Therapeutics Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Mycosis Fungoides Therapeutics Sales Value (2021-2032)
  16. 6.6.2 South America Mycosis Fungoides Therapeutics Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Mycosis Fungoides Therapeutics Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Mycosis Fungoides Therapeutics Sales Value Share by Country, 2025 VS 2032
7 Mycosis Fungoides Therapeutics Country-level Value Analysis
  1. 7.1 Global Mycosis Fungoides Therapeutics Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Mycosis Fungoides Therapeutics Sales Value by Country (2021-2032)
  3. 7.2.1 Global Mycosis Fungoides Therapeutics Sales Value by Country (2021-2026)
  4. 7.2.2 Global Mycosis Fungoides Therapeutics Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Mycosis Fungoides Therapeutics Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Mycosis Fungoides Therapeutics Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Mycosis Fungoides Therapeutics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Kyowa Kirin Co. Ltd.
  2. 8.1.1 Kyowa Kirin Co. Ltd. Company Information
  3. 8.1.2 Kyowa Kirin Co. Ltd. Business Overview
  4. 8.1.3 Kyowa Kirin Co. Ltd. Mycosis Fungoides Therapeutics Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Kyowa Kirin Co. Ltd. Mycosis Fungoides Therapeutics Product Portfolio
  6. 8.1.5 Kyowa Kirin Co. Ltd. Recent Developments
  7. 8.2 Takeda Pharmaceutical Co. Ltd.
  8. 8.2.1 Takeda Pharmaceutical Co. Ltd. Company Information
  9. 8.2.2 Takeda Pharmaceutical Co. Ltd. Business Overview
  10. 8.2.3 Takeda Pharmaceutical Co. Ltd. Mycosis Fungoides Therapeutics Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Takeda Pharmaceutical Co. Ltd. Mycosis Fungoides Therapeutics Product Portfolio
  12. 8.2.5 Takeda Pharmaceutical Co. Ltd. Recent Developments
  13. 8.3 Eisai Co. Ltd.
  14. 8.3.1 Eisai Co. Ltd. Company Information
  15. 8.3.2 Eisai Co. Ltd. Business Overview
  16. 8.3.3 Eisai Co. Ltd. Mycosis Fungoides Therapeutics Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Eisai Co. Ltd. Mycosis Fungoides Therapeutics Product Portfolio
  18. 8.3.5 Eisai Co. Ltd. Recent Developments
  19. 8.4 Merck & Co. Inc.
  20. 8.4.1 Merck & Co. Inc. Company Information
  21. 8.4.2 Merck & Co. Inc. Business Overview
  22. 8.4.3 Merck & Co. Inc. Mycosis Fungoides Therapeutics Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Merck & Co. Inc. Mycosis Fungoides Therapeutics Product Portfolio
  24. 8.4.5 Merck & Co. Inc. Recent Developments
  25. 8.5 Soligenix Inc.
  26. 8.5.1 Soligenix Inc. Company Information
  27. 8.5.2 Soligenix Inc. Business Overview
  28. 8.5.3 Soligenix Inc. Mycosis Fungoides Therapeutics Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Soligenix Inc. Mycosis Fungoides Therapeutics Product Portfolio
  30. 8.5.5 Soligenix Inc. Recent Developments
  31. 8.6 Seattle Genetics Inc.
  32. 8.6.1 Seattle Genetics Inc. Company Information
  33. 8.6.2 Seattle Genetics Inc. Business Overview
  34. 8.6.3 Seattle Genetics Inc. Mycosis Fungoides Therapeutics Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Seattle Genetics Inc. Mycosis Fungoides Therapeutics Product Portfolio
  36. 8.6.5 Seattle Genetics Inc. Recent Developments
  37. 8.7 Horizon Therapeutics Plc
  38. 8.7.1 Horizon Therapeutics Plc Company Information
  39. 8.7.2 Horizon Therapeutics Plc Business Overview
  40. 8.7.3 Horizon Therapeutics Plc Mycosis Fungoides Therapeutics Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Horizon Therapeutics Plc Mycosis Fungoides Therapeutics Product Portfolio
  42. 8.7.5 Horizon Therapeutics Plc Recent Developments
  43. 8.8 Helsinn Healthcare SA
  44. 8.8.1 Helsinn Healthcare SA Company Information
  45. 8.8.2 Helsinn Healthcare SA Business Overview
  46. 8.8.3 Helsinn Healthcare SA Mycosis Fungoides Therapeutics Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Helsinn Healthcare SA Mycosis Fungoides Therapeutics Product Portfolio
  48. 8.8.5 Helsinn Healthcare SA Recent Developments
  49. 8.9 Celgene Corp.
  50. 8.9.1 Celgene Corp. Company Information
  51. 8.9.2 Celgene Corp. Business Overview
  52. 8.9.3 Celgene Corp. Mycosis Fungoides Therapeutics Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Celgene Corp. Mycosis Fungoides Therapeutics Product Portfolio
  54. 8.9.5 Celgene Corp. Recent Developments
  55. 8.10 Azurity Pharmaceuticals Inc.
  56. 8.10.1 Azurity Pharmaceuticals Inc. Company Information
  57. 8.10.2 Azurity Pharmaceuticals Inc. Business Overview
  58. 8.10.3 Azurity Pharmaceuticals Inc. Mycosis Fungoides Therapeutics Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Azurity Pharmaceuticals Inc. Mycosis Fungoides Therapeutics Product Portfolio
  60. 8.10.5 Azurity Pharmaceuticals Inc. Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst